slot app
Save up to $1,100 on this Sony Bravia 7 and soundbar bundle at Amazon for Black Friday
Jones Walker Welcomes 16 AssociatesStocks jumped at Monday's open and bond yields retreated as markets welcomed President-elect Donald Trump's nomination of Scott Bessent to be his Treasury secretary. The Dow Jones Industrial Average closed at a new all-time high and the S&P 500 hit a new intraday high early in the opening session of a holiday-shortened week highlighted by a packed economic calendar. In a Friday evening post on Truth Social , Trump described Bessent, the former chief investment strategist of Soros Fund Management, as "one of the world's foremost international investors and geopolitical and economic strategists." The president-elect added, "Scott's story is that of the American Dream." Bessent is also the co-founder of Key Square Group, a macro-focused investment firm that specializes in analyzing economic, political and market conditions to trade across asset classes, including currencies and interest rates as well as commodities and stocks. Subscribe to Kiplinger’s Personal Finance Be a smarter, better informed investor. Sign up for Kiplinger’s Free E-Newsletters Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail. Profit and prosper with the best of expert advice - straight to your e-mail. Wall Street is positive about Bessent because of his success as an investor and for the moderating influence he is expected to exert within the Trump administration. In a November 15 op-ed for Fox News on the subject of Trump's primary tool of economic policy, Bessent writes, "The truth is that tariffs have a long and storied history as both a revenue-raising tool and a way of protecting strategically important industries in the U.S. President-elect Trump has added a third leg to the stool: tariffs as a negotiating tool with our trading partners." "The nomination of Scott Bessent to be U.S. Treasury Secretary has been a catalyst for lower bond yields, higher equity indices and a weaker dollar this morning," writes Kit Juckes , chief forex strategist at Societe Generale. The nomination is a palliative for investors "worried about the size of the U.S. budget deficit and the inflationary impact of tariffs. Whether he can help get the U.S. to 3% GDP growth and a 3% budget deficit time will tell, but for now, he has changed the market mood, if nothing else," Juckes concludes. The yield on the 10-year U.S. Treasury note declined by 15 basis points to 4.27%, while the yield on the 2-year dipped 10 basis points to 4.27%. The Dow backed off its intraday high but still closed at a record level, rising 1% to 44,736. The S&P 500 also slipped from its intraday high but held on for a 0.3% gain to 5,987. The Nasdaq Composite , meanwhile, edged up 0.3% to 19,054. Stocks on the move Earnings season is nearing an end, with 95% of the S&P 500 having reported so far. FactSet Senior Earnings Analyst John Butters notes that with numbers from 462 of the firms in the index, 75% have reported positive earnings per share (EPS) surprises and 61% have reported positive revenue surprises. "For Q3 2024," Butters writes, "the blended (year-over-year) earnings growth rate for the S&P 500 is 5.8%. If 5.8% is the actual growth rate for the quarter, it will mark the 5th straight quarter of year-over-year earnings growth for the index." Bath & Body Works ( BBWI ) was deleted from S&P 500 on October 1, but the stock surged 16.5% after the specialty retailer beat top- and bottom-line expectations for its third quarter and raised its full-year outlook. "Our strong results exceeded the high end of our net sales and earnings per diluted share guidance," said Bath & Body Works CEO Gina Boswell in a statement. "As a result, we are raising our full-year guidance to fully reflect this outperformance." Wall Street remains optimistic about BBWI. According to S&P Global Market Intelligence , the consensus recommendation is Buy, and the average 12-month price target for the consumer discretionary stock is $42.76. Even after Monday's strong showing that's about 20% upside. Macy's ( M ) stock, which was removed from the S&P 500 in April 2020, fell 2.3% after the retailer announced preliminary results for its third quarter, during which sales declined 2.4% year over year. Macy's also announced a delay in filing its quarterly statement with the Securities and Exchange Commission (SEC) after management "identified an issue related to delivery expenses in one of its accrual accounts." Macy's determined a single employee "intentionally made erroneous accounting accrual entries to hide approximately $132 to $154 million of cumulative delivery expenses." The big picture remains murky for the iconic retailer. "It has major disadvantages vs peers around price, product, and service," writes UBS Global Research analyst Jay Sole in a November 18 note. "We believe these dynamics should lead to continuous net losses. M's current stock price does not reflect long-term earnings-per-share challenges, in our view." Incoming data With third-quarter earnings season winding down, investors have a packed economic calendar to capture their attention this week. Note that markets will be closed on Thursday and will shut down early on Friday for the Thanksgiving holiday. Tuesday's releases include the S&P CoreLogic Case-Shiller Home Price Indices at 9 am Eastern time as well as a consumer confidence survey from The Conference Board and new home sales data from the Census Bureau at 10 am. The Federal Reserve will publish the minutes from the November FOMC meeting at 2 pm. And it's a particularly big Wednesday, with initial jobless claims coming in a day early because of the holiday on Thursday. We'll also see data on durable goods orders, retail and wholesale inventories, the U.S. trade balance and the second read on third-quarter GDP. The main event is the release of the Personal Consumption and Expenditures Price Index (PCE) series at 10 am. PCE is the Fed's preferred measure of inflation . "Based on the depth and breadth of the transitions in progress at this time in monetary policy, on Capitol Hill and in the change of Administration along with what appears to be a watershed period in technological innovation, some market participants can't help but wonder if they should be adjusting their portfolio exposures for a myriad of outcomes espoused by various market pundits with widely divergent views and opinions," writes John Stoltzfus of Oppenheimer Asset Management. "For one, while the pace of inflation appears to be slowing enabling the Fed to move towards more rate cuts in the months ahead," Stoltzfus observes, "the latest CPI numbers showed some inflation stickiness that has proved irksome to those with great expectations for more frequent and deeper interest rate cuts." According to the CME FedWatch tool, as of Monday afternoon, there is a 55.9% chance the Federal Open Market Committee cuts the target range for the federal funds rate by 25 basis points at its December 18 meeting. Related content Stock Picks That Billionaires Love Best Bond Funds to Buy Now Six Ways Trump Could Change Your Retirement
How chef and activist Andrew Zimmern practices gratitude at the Thanksgiving tableParainfluenza Virus Infection Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials | Ansun Biopharma, AlloVir, Ansun Biopharma 11-21-2024 08:51 PM CET | Health & Medicine Press release from: DelveIinsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Parainfluenza Virus Infection pipeline constitutes 5+ key companies continuously working towards developing 5+ Parainfluenza Virus Infection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Parainfluenza Virus Infection Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parainfluenza Virus Infection Market. The Parainfluenza Virus Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Parainfluenza Virus Infection Pipeline Report: https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Parainfluenza Virus Infection treatment therapies with a considerable amount of success over the years. •Parainfluenza Virus Infection companies working in the treatment market are Ansun Biopharma, AlloVir, Ansun Biopharma, and others, are developing therapies for the Parainfluenza Virus Infection treatment •Emerging Parainfluenza Virus Infection therapies in the different phases of clinical trials are- DAS181, ALVR106, Oplunofusp, and others are expected to have a significant impact on the Parainfluenza Virus Infection market in the coming years. Parainfluenza Virus Infection Overview Parainfluenza virus infection is a respiratory illness caused by human parainfluenza viruses (HPIVs), a group of viruses that primarily affect the respiratory tract. These infections are common, especially in children, and can cause a range of illnesses, from mild colds to severe conditions like croup, bronchitis, and pneumonia. HPIVs spread through respiratory droplets or contact with contaminated surfaces. Symptoms often include fever, cough, runny nose, and difficulty breathing. While most cases resolve without complications, severe infections may occur in immunocompromised individuals, the elderly, and young children. Treatment focuses on symptom relief, as there is no specific antiviral therapy for HPIV. Get a Free Sample PDF Report to know more about Parainfluenza Virus Infection Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Parainfluenza Virus Infection Drugs Under Different Phases of Clinical Development Include: •DAS181: Ansun Biopharma •ALVR106: AlloVir •Oplunofusp: Ansun Biopharma Parainfluenza Virus Infection Route of Administration Parainfluenza Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Parainfluenza Virus Infection Molecule Type Parainfluenza Virus Infection Products have been categorized under various Molecule types, such as •Monoclonal Antibody •Peptides •Polymer •Small molecule •Gene therapy Parainfluenza Virus Infection Pipeline Therapeutics Assessment •Parainfluenza Virus Infection Assessment by Product Type •Parainfluenza Virus Infection By Stage and Product Type •Parainfluenza Virus Infection Assessment by Route of Administration •Parainfluenza Virus Infection By Stage and Route of Administration •Parainfluenza Virus Infection Assessment by Molecule Type •Parainfluenza Virus Infection by Stage and Molecule Type DelveInsight's Parainfluenza Virus Infection Report covers around 5+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Parainfluenza Virus Infection product details are provided in the report. Download the Parainfluenza Virus Infection pipeline report to learn more about the emerging Parainfluenza Virus Infection therapies at: https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Parainfluenza Virus Infection Therapeutics Market include: Key companies developing therapies for Parainfluenza Virus Infection are - AlloVir, Ansun Biopharma, Moderna Therapeutics, and others. Parainfluenza Virus Infection Pipeline Analysis: The Parainfluenza Virus Infection pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Parainfluenza Virus Infection with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parainfluenza Virus Infection Treatment. •Parainfluenza Virus Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Parainfluenza Virus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parainfluenza Virus Infection market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Parainfluenza Virus Infection drugs and therapies- https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Parainfluenza Virus Infection Pipeline Market Drivers •Rising Incidence, Advancements in Diagnostic Tools, Growing Awareness, Development of Vaccines, Supportive Healthcare Policies, are some of the important factors that are fueling the Parainfluenza Virus Infection Market. Parainfluenza Virus Infection Pipeline Market Barriers •However, Lack of Specific Treatments, High R&D Costs, Limited Awareness in Low-Income Regions, Seasonal Variability, Regulatory Challenges, and other factors are creating obstacles in the Parainfluenza Virus Infection Market growth. Scope of Parainfluenza Virus Infection Pipeline Drug Insight •Coverage: Global •Key Parainfluenza Virus Infection Companies: Ansun Biopharma, AlloVir, Ansun Biopharma, and others •Key Parainfluenza Virus Infection Therapies: DAS181, ALVR106, Oplunofusp, and others •Parainfluenza Virus Infection Therapeutic Assessment: Parainfluenza Virus Infection current marketed and Parainfluenza Virus Infection emerging therapies •Parainfluenza Virus Infection Market Dynamics: Parainfluenza Virus Infection market drivers and Parainfluenza Virus Infection market barriers Request for Sample PDF Report for Parainfluenza Virus Infection Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Parainfluenza Virus Infection Report Introduction 2. Parainfluenza Virus Infection Executive Summary 3. Parainfluenza Virus Infection Overview 4. Parainfluenza Virus Infection- Analytical Perspective In-depth Commercial Assessment 5. Parainfluenza Virus Infection Pipeline Therapeutics 6. Parainfluenza Virus Infection Late Stage Products (Phase II/III) 7. Parainfluenza Virus Infection Mid Stage Products (Phase II) 8. Parainfluenza Virus Infection Early Stage Products (Phase I) 9. Parainfluenza Virus Infection Preclinical Stage Products 10. Parainfluenza Virus Infection Therapeutics Assessment 11. Parainfluenza Virus Infection Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Parainfluenza Virus Infection Key Companies 14. Parainfluenza Virus Infection Key Products 15. Parainfluenza Virus Infection Unmet Needs 16 . Parainfluenza Virus Infection Market Drivers and Barriers 17. Parainfluenza Virus Infection Future Perspectives and Conclusion 18. Parainfluenza Virus Infection Analyst Views 19. Appendix 20. About DelveInsight Latest Reports: •Sglt2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market •Electroencephelographs Pipeline Insight: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight •Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market •Dental Implants And Prosthesis Market: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market •Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market •Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market •Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.
6 Pope: Didn’t have much to do other than the goals, where he was let down by those in front. 6 Livramento: Tried to drive forward at every opportunity, especially in the first half. 6 Schar: Solid enough. Didn’t have an awful lot to do. 4 Kelly : Lost Soucek for West Ham’s crucial early opener. Good tackle on Summerville in second half but booked for foul on Bowen. Failed to take big chance in absence of Burn. 7 Hall: Newcastle’s best player again. Lively and full of running and positive intent. Went close on a couple of occasions. 5 Longstaff: Never really settled and got a grip of the game. Replaced on the hour. 5 Willock: Worked hard and went close with one chance but midfield a bit chaotic at times .Was hurt in accidental clash with his own teammate Longstaff and replaced at the break. 6 Bruno : Brilliant first half pass to create chance for Isak. Robbed of possession in build-up to decisive second goal. 5 Gordon: Missed glorious first half chance when he was denied by Fabianski and failed to make the most of several promising openings. 5 Joelinton: Couldn’t get into the game. 6 Isak: Promising start with disallowed goal and a threat in the first half but starved of service after the break. Substitutes: 5 Barnes (for Willock, 46): Failed to make an impact from the bench. 6 Tonali (for Longstaff, 57): Change didn’t have the desired effect. Tidy enough but Newcastle ran out of steam and ideas. Wilson (for Gordon, 68): N/A Murphy (for Joelinton, 69): N/A Trippier (for Bruno, 84): N/A Subs not used : Dubravka, Almiron, Targett, Osula WEST HAM: Fabiański 7, Wan-Bissaka 7, Todibo 5 (Mavropanos, 56), Kilman 6, Emerson 7 (Coufal, 75), Soler 8 (Rodríguez, 84), Souček 8, Paquetá 8, Summerville 7 (Irving, 84), Bowen 8, Antonio 7 (Ings, 75) SUBS NOT USED: Areola (GK), Cresswell, Scarles, Luis Guilherme Man of the Match : Bowen. West Ham’s captain was a threat and used the ball superbly throughout. He made the decisive second goal for Wan-Bissaka.
None
Chronister is the second person selected by the president-elect to bow out quickly after being nominated for a position requiring Senate confirmation.Judge hears closing arguments on whether Google's advertising tech constitutes a monopolyWest Ham 2-0 Newcastle (Nov 25, 2024) Game Analysis - ESPN
ALEXANDRIA, Va. (AP) — Google, already facing a possible breakup of the company over its ubiquitous search engine , is fighting to beat back another attack by the U.S. Department of Justice alleging monopolistic conduct, this time over technology that puts online advertising in front of consumers. The Justice Department and Google made closing arguments Monday in a trial alleging Google's advertising technology constitutes an illegal monopoly. U.S. District Judge Leonie Brinkema in Alexandria, Virginia, will decide the case and is expected to issue a written ruling by the end of the year. If Brinkema finds Google has engaged in illegal, monopolistic conduct, she will then hold further hearings to explore what remedies should be imposed. The Justice Department, along with a coalition of states, has already said it believes Google should be forced to sell off parts of its ad tech business, which generates tens of billions of dollars annually for the Mountain View, California-based company. After roughly a month of trial testimony earlier this year, the arguments in the case remain the same. During three hours of arguments Monday, Brinkema, who sometimes tips her hand during legal arguments, did little to indicate how she might rule. She did, though, question the applicability of a key antitrust case Google cites in its defense. The Justice Department contends Google built and maintained a monopoly in “open-web display advertising,” essentially the rectangular ads that appear on the top and right-hand side of the page when one browses websites. Google dominates all facets of the market. A technology called DoubleClick is used pervasively by news sites and other online publishers, while Google Ads maintains a cache of advertisers large and small looking to place their ads on the right webpage in front of the right consumer. In between is another Google product, AdExchange, that conducts nearly instantaneous auctions matching advertisers to publishers. In court papers, Justice Department lawyers say Google “is more concerned with acquiring and preserving its trifecta of monopolies than serving its own publisher and advertiser customers or winning on the merits.” As a result, content providers and news organizations have never been able to generate the online revenue they should due to Google’s excessive fees for brokering transactions between advertisers and publishers, the government says. Google argues the government's case improperly focuses on a narrow niche of online advertising. If one looks more broadly at online advertising to include social media, streaming TV services, and app-based advertising, Google says it controls as little as 10% of the market, a share that is dwindling as it faces increased and evolving competition. Google alleges in court papers that the government’s lawsuit “boil(s) down to the persistent complaints of a handful of Google’s rivals and several mammoth publishers.” Google also says it has invested billions in technology that facilitates the efficient match of advertisers to interested consumers and it should not be forced to share its technology and success with competitors. “Requiring a company to do further engineering work to make its technology and customers accessible by all of its competitors on their preferred terms has never been compelled by U.S. antitrust law,” the company wrote. Brinkema, during Monday's arguments, also sought clarity on Google’s market share, a number the two sides dispute, depending on how broadly the market is defined. Historically, courts have been unwilling to declare an illegal monopoly in markets in which a company holds less than a 70% market share. Google says that when online display advertising is viewed as a whole, it holds only a 10% market share, and dwindling. The Justice Department contends, though, that when focusing on open-web display advertising, Google controls 91% of the market for publisher ad servers and 87% of the market for advertiser ad networks. Google says that the “open web display advertising” market is gerrymandered by the Justice Department to make Google look bad, and that nobody in the industry looks at that category of ads without considering the ability of advertisers to switch to other forms of advertising, like in mobile apps. The Justice Department also contends that the public is harmed by the excessive rates Google charges to facilitate ad purchases, saying the company takes 36 cents on the dollar when it facilitates the transaction end to end. Google says its “take rate” has dropped to 31% and continues to decrease, and it says that rate is lower than that of its competitors. “When you have an integrated system, one of the benefits is lower prices," Google lawyer Karen Dunn said Monday. The Virginia case is separate from an ongoing lawsuit brought against Google in the District of Columbia over its namesake search engine. In that case, the judge determined it constitutes an illegal monopoly but has not decided what remedy to impose. The Justice Department said last week it will seek to force Google to sell its Chrome web browser , among a host of other penalties. Google has said the department's request is overkill and unhinged from legitimate regulation. In Monday's arguments, Justice Department lawyer Aaron Teitelbaum cited the search engine case when he highlighted an email from a Google executive, David Rosenblatt, who said in a 2009 email that Google’s goal was to “do to display what Google did to search," which Teitelbaum said showed the company's intent to achieve market dominance. “Google did not achieve its trifecta of monopolies by accident,” Teitelbaum said.Marshall's 17 lead Albany over Puerto Rico-Mayaguez 93-50
A shooter kills UnitedHealthcare's CEO in an ambush in New York, police say NEW YORK (AP) — UnitedHealthcare’s CEO has been shot and killed in what police say is a “brazen, targeted attack” outside a Manhattan hotel where the health insurer was holding its investor conference. The shooting rattled the city and set off a massive dragnet hours before the annual Rockefeller Center Christmas tree lighting. Police say 50-year-old Brian Thompson was shot around 6:45 a.m. Wednesday as he walked alone to the New York Hilton Midtown from a nearby hotel. New York City Police Commissioner Jessica Tisch says the shooter appeared to be “lying in wait for several minutes” before approaching Thompson from behind and opening fire. Police have not yet established a motive. UnitedHealthcare CEO kept a low public profile. Then he was shot to death in New York NEW YORK (AP) — Brian Thompson led one of the biggest health insurers in the US but was unknown to the millions of people his decisions affected. The fatal shooting of UnitedHealthcare's chief executive on a midtown Manhattan sidewalk early Wednesday swiftly became a mystery that riveted the nation. Police say it was a targeted killing. Thompson was 50. He had run health care giant UnitedHealth Group Inc.'s insurance business since 2021. It provides health coverage for more than 49 million Americans. He had worked at the company for 20 years. The business run by Thompson brought in $281 billion in revenue last year. Thompson's $10.2 million annual compensation package made him one of the company’s highest-paid executives. Hegseth fights to save Pentagon nomination as sources say Trump considers DeSantis WASHINGTON (AP) — Pete Hegseth, Donald Trump’s Pentagon pick, is fighting to hold on to his Cabinet nomination amid growing questions about his personal conduct as the president-elect’s team considers alternatives, including Florida Gov. Ron DeSantis. But Hegseth says, “We’re not backing down one bit." The Trump transition team is concerned about Hegseth’s path to Senate confirmation and is actively looking at potential replacements, according to a person familiar with the matter. Hegseth is under pressure as senators weigh a series of allegations that have surfaced against him. Beyond DeSantis, there have been discussions about shifting Michael Waltz, who was named by Trump as his national security adviser, to the Defense Department Supreme Court seems likely to uphold Tennessee's ban on medical treatments for transgender minors WASHINGTON (AP) — Hearing a high-profile culture-war clash, the Supreme Court on Wednesday seemed likely to uphold Tennessee’s ban on gender-affirming care for minors. The justices’ decision, not expected for several months, could affect similar laws enacted by another 25 states and a range of other efforts to regulate the lives of transgender people, including which sports competitions they can join and which bathrooms they can use. The case is being weighed by a conservative-dominated court after a presidential election in which Donald Trump and his allies promised to roll back protections for transgender people. The Biden administration’s top Supreme Court lawyer warned a decision favorable to Tennessee also could be used to justify nationwide restrictions on transgender healthcare for minors. Peter Navarro served prison time related to Jan. 6. Now Trump is bringing him back as an adviser WASHINGTON (AP) — President-elect Donald Trump is bringing Peter Navarro back to the White House for his second administration. Trump announced Wednesday on Truth Social that Navarro will serve as a senior counselor for trade and manufacturing. He was a trade adviser in Trump's first term. Navarro served four months in prison after being held in contempt of Congress for defying a subpoena from the House committee that investigated the Jan. 6 attack on the U.S. Capitol. Trump also chose Daniel Driscoll as Army secretary, Jared Isaacman as NASA administrator and Adam Boehler as special presidential envoy for hostage affairs. Israeli strikes on a Gaza tent camp kill at least 21 people, hospital says KHAN YOUNIS, Gaza Strip (AP) — A Palestinian health official said Wednesday that at least 21 people were killed in Israeli strikes on a camp housing displaced people in Gaza. The Israeli military said it struck senior Hamas militants. The strikes hit in the Muwasi area, a sprawling coastal camp housing hundreds of thousands of displaced people. It came after Israeli forces struck targets in other areas of Gaza. According to Palestinian medics, strikes in central Gaza killed eight people, including four children. The war in Gaza is nearly 14 months old and showing no end in sight, despite international efforts to revive negotiations toward a ceasefire. South Korean President Yoon's martial law declaration raises questions over his political future SEOUL, South Korea (AP) — President Yoon Suk Yeol’s stunning martial law declaration lasted just hours, but experts say it raised serious questions about his ability to govern for the remaining 2 1/2 years of his term. The opposition-controlled parliament overturned the edict, and his rivals on Wednesday took steps to impeach him. Yoon's move baffled many experts. One analyst called his action “political suicide.” Yoon’s political fate may depend on whether a large number of people in coming days take to the streets to push for his ouster. Yoon hasn't commented on the impeachment bid. But the political instability he unleashed could make it more difficult for his government to nurse a decaying economy. French lawmakers vote to oust prime minister in the first successful no-confidence vote since 1962 PARIS (AP) — France’s far-right and left-wing lawmakers have joined together to vote on a no-confidence motion prompted by budget disputes that forces Prime Minister Michel Barnier and his Cabinet to resign. The National Assembly approved the motion by 331 votes. A minimum of 288 were needed. President Emmanuel Macron insisted he will serve the rest of his term until 2027. However, he will need to appoint a new prime minister for the second time after July’s legislative elections led to a deeply divided parliament. Macron will address the French on Thursday evening, his office said, without providing details. Barnier is expected to formally resign by then. White House says at least 8 US telecom firms, dozens of nations impacted by China hacking campaign WASHINGTON (AP) — A top White House official says at least eight U.S. telecom firms and dozens of nations have been impacted by a Chinese hacking campaign. Deputy national security adviser Anne Neuberger offered the new details Wednesday about the breadth of the sprawling Chinese hacking campaign that gave officials in Beijing access to private texts and phone conversations of an unknown number of Americans. Neuberger divulged the scope of the hack a day after the FBI and the Cybersecurity and Infrastructure Security Agency issued guidance intended to help root out the hackers and prevent similar cyberespionage in the future. White House officials cautioned that a number of telecommunication firms and countries impacted could still grow. Harris found success with women who have cats, but Trump got the dog owner vote: AP VoteCast WASHINGTON (AP) — The lead-up to the 2024 election was all about cat owners. But in the end, the dogs had their day. Donald Trump won more than half of voters who own either cats or dogs, and he had with a big assist from dog owners. That's according to AP VoteCast, a survey of more than 120,000 voters. Dog owners were much more likely to support Trump over Kamala Harris. Cat owners were evenly split between the two candidates. Harris did end up decisively winning support from women who own a cat but no dog. Past comments by Trump's running mate, JD Vance, about “childless cat ladies” briefly became a campaign issue.
Granisetron Market Is Likely to Experience a Tremendous Growth in Near Future 11-25-2024 09:19 PM CET | Health & Medicine Press release from: AMA Research & Media LLP The latest study released on the global 'Granisetron' market by AMA Research evaluates market size, trend, and forecast to 2030. The 'Granisetron' market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors. Get free access to Sample Report in PDF Version along with Graphs and Figures @ https://www.advancemarketanalytics.com/sample-report/83554-global-granisetron-market?utm_source=OpenPR/utm_medium=Rahul Some of the key players profiled in the study are: Kyowa Kirin (Japan), Heron Therapeutics (United States), Fresenius Kabi (Germany), Hikma Pharmaceuticals (United Kingdom), Teva (Israel), Sandoz (Germany), Wockhardt (India), Aristo Pharmaceuticals Pvt Ltd (India), Mankind Pharma Ltd(India), Cipla Ltd (India) Granisetron is used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy. Granisetron is in a class of medications called 5-HT3 receptor antagonists. It works by blocking serotonin, a natural substance in the body that causes nausea and vomiting Keep yourself up-to-date with latest market trends and changing dynamics due to COVID Impact and Economic Slowdown globally. Maintain a competitive edge by sizing up with available business opportunity in Granisetron Market various segments and emerging territory. Influencing Market Trend •Increasing pharmaceutical research and funding Market Drivers •The rise in the prevalence of cancers Opportunities: •Increasing demand for personalized medicine Challenges: •Key competition between players Analysis by Application (Chemotherapy, Radiotherapy, Nausea, Gastroparesis, Postoperative), Forms (Injection, Tablet, Syrup, Tablet, Oral Drops), Drug type (Generic drug, Patent based drug), End User (Hospital, Drug Store) Have Any Questions Regarding Global Granisetron Market Report, Ask Our Experts@ https://www.advancemarketanalytics.com/enquiry-before-buy/83554-global-granisetron-market?utm_source=OpenPR/utm_medium=Rahul The regional analysis of Global Granisetron Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world. Whereas, owing to rising no. of research activities in countries such as China, India, and Japan, Asia Pacific region is also expected to exhibit higher growth rate the forecast period 2024-2030. Table of Content Chapter One: Industry Overview Chapter Two: Major Segmentation (Classification, Application and etc.) Analysis Chapter Three: Production Market Analysis Chapter Four: Sales Market Analysis Chapter Five: Consumption Market Analysis Chapter Six: Production, Sales and Consumption Market Comparison Analysis Chapter Seven: Major Manufacturers Production and Sales Market Comparison Analysis Chapter Eight: Competition Analysis by Players Chapter Nine: Marketing Channel Analysis Chapter Ten: New Project Investment Feasibility Analysis Chapter Eleven: Manufacturing Cost Analysis Chapter Twelve: Industrial Chain, Sourcing Strategy and Downstream Buyers Read Executive Summary and Detailed Index of full Research Study @ https://www.advancemarketanalytics.com/reports/83554-global-granisetron-market?utm_source=OpenPR/utm_medium=Rahul Highlights of the Report • The future prospects of the global Granisetron market during the forecast period 2024-2030 are given in the report. • The major developmental strategies integrated by the leading players to sustain a competitive market position in the market are included in the report. • The emerging technologies that are driving the growth of the market are highlighted in the report. • The market value of the segments that are leading the market and the sub-segments are mentioned in the report. • The report studies the leading manufacturers and other players entering the global Granisetron market. Contact Us: Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA - 08837 Phone: +1(201) 7937323, +1(201) 7937193 sales@advancemarketanalytics.com About Author: AMA Research & Media is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies' revenues. Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enables clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As. This release was published on openPR.
Gretchen McKay | (TNS) Pittsburgh Post-Gazette Beans are kind of like the your best friend from high school — nearly forgotten but always ready to step back into the limelight and help out an old pal when needed. As gorgeously (and tantalizingly) demonstrated in Rancho Gordo’s new cookbook, “The Bean Book: 100 Recipes for Cooking with All Kinds of Beans” (Ten Speed, $35), beans are indeed a magical fruit, though not in the way you heard as a kid. Classified as both a vegetable and a plant-based protein in the USDA’s Dietary Guidelines for Americans, beans and other legumes can be the ingredient you build an entire vegetarian or veggie-forward meal around. Or, they can help an economical cook stretch a dish twice as far with nutritious calories. A healthful and shelf-staple plant food — they last for years when dried — beans have been among a home cook’s most reliable pantry items for a very long time. (Common beans (Phaseolus vulgaris) are thought to have been grown in Mexico more than 7,000 years ago.) That’s why, for some, they’re often something of an afterthought, especially if the only time you ate them as a kid was when your mom tossed kidney beans into a pot of beef chili or made baked beans (with brown sugar and bacon, please!) for a family cookout. Related Articles Restaurants Food and Drink | Do not wash your turkey and other Thanksgiving tips to keep your food safe Restaurants Food and Drink | Frying a turkey this Thanksgiving? Here are some tips to stay safe Restaurants Food and Drink | 5 budget-friendly Thanksgiving dinner ideas Restaurants Food and Drink | The future of Thanksgiving is takeout and hosts couldn’t be happier Restaurants Food and Drink | A starry Thanksgiving: Recipes beloved by Donna Kelce, Eric Stonestreet, Taylor Swift Vegetarians have always appreciated their versatility and nutritional punch, and because they’re cheap, they also were quite popular during the Great Depression and World War II as C rations. Sales also peaked during the coronavirus pandemic, when shoppers stockpiled long-lasting pantry essentials. It wasn’t until Rancho Gordo, a California-based bean company, trotted out its branded packages of colorful heirloom beans that the plant began to take on cult status among some shoppers. Unlike the bean varieties commonly found in even the smallest grocery stores, heirloom beans are mostly forgotten varieties that were developed on a small scale for certain characteristics, with seeds from the best crops passed down through the generations. The result is beans that are fresher and more colorful than mass-produced beans, and come in different shapes and sizes. They also have a more complex and intense flavor, fans say. “The Bean Book” dishes up dozens of different ways to cook Rancho Gordo’s 50 heirloom bean varieties, which include red-streaked cranberry beans, mint-green flageolets, black and classic garbanzos and (my favorite) vaquero — which wear the same black-and-white spots as a Holstein cow. Other gotta-try varieties (if just for the name) include eye of the goat, European Soldier, Jacob’s Cattle and Good Mother Stallard, a purple bean with cream-colored flecks. “The very good news is that you have to work extra hard to mess up a pot of beans, and it’s not difficult to make an excellent pot,” Steve Sando writes in the book’s foreword. “The even better news is that you become a better cook with each pot you make.” Not convinced? Here are five reasons to jump on the bean bandwagon: Even the smallest grocery store will have a selection of dried and canned beans. Common varieties include black, cannellini (white kidney), Great Northern, pinto, navy, kidney, Lima and garbanzo (chickpea) beans. Even when they’re not on sale, beans are a bargain at the supermarket. Many varieties cost less than $1 a can, and dried beans are an economical way to build a menu. I paid $1.25 for a one-pound bag of cranberry beans, a smooth and velvety bean with a slightly nutty flavor, at my local grocery store. Rancho Gordo’s heirloom beans cost substantially more. (They run $6.25-$7.50 for a one-pound bag, with free shipping on orders over $50.) But they are sold within a year of harvest, which makes them more flavorful and tender. A bag also comes with cooking instructions and recipe suggestions, and the quality is outstanding. Plus, after cooking their beans with aromatics, “you are left with essentially free soup,” Sando writes in the cookbook. “If you drain properly cooked and seasoned beans, the liquid you are left with is delicious.” Beans are a great source of plant-based protein and both soluble and insoluble fiber, and they include essential minerals like iron, magnesium and potassium. If you’re watching your weight or following a particular diet, beans are naturally free of fat, sodium and cholesterol and are rich in complex carbohydrates. They also contain antioxidants and folate. And if you’re vegan or vegetarian, most types of dry beans are rich sources of iron. The U.S. Dietary Guidelines for Americans recommends eating 1-3 cups of legumes, including beans, per week Dry beans have to be soaked overnight, but cooking them is easy. They can be cooked on the stovetop, in a slow cooker, in the pressure cooker and in the oven. Canned beans are even easier — just rinse and drain, and they’re ready to go. Beans can be used in so many different dishes. They can be made into soup, salad or dips, top nachos, add some heft to a casserole or be mashed into the makings of a veggie burger. You also can add them to brownies and other baked goods, toss them with pasta, add them to chili or a rice bowl or stuff them into a taco or burrito. Check out these four recipes: PG tested This light and creamy vegetarian soup benefits from a surprising garnish, roasted shiitake mushrooms, which taste exactly like bacon. For soup 1/4 cup olive oil 1 medium yellow onion, chopped 2 celery stalks, chopped 1 medium carrot, scrubbed and chopped 6 garlic cloves, finely grated or pressed 2 sprigs fresh thyme, plus more for garnish 1/2 teaspoon sea salt 1/4 teaspoon pepper 4 cups vegetable broth 2 15-ounce cans cannellini beans, drained and rinsed For bacon 8 ounces shiitake mushrooms, caps cut into 1/8 -inch slices 2 tablespoons olive oil 1/4 teaspoons fine sea salt To finish Plant-based milk Chili oil, for drizzling Preheat oven to 400 degrees. Make soup: In large pot, heat oil over medium heat until it shimmers. Add onion, celery, carrot, garlic, thyme, salt and pepper. Cook, stirring occasionally, until vegetables are fragrant and tender, 8-10 minutes. Add vegetable stock and beans, increase heat to high and bring mixture to a boil. Reduce heat to medium and simmer until thickened, 12-14 minutes. Meanwhile, make the bacon: Spread shiitake mushrooms into a single layer on a sheet pan, drizzle with olive oil, sprinkle with salt and pepper and toss to combine. Bake until browned and crispy, 18-20 minutes, rotating pan front to back and tossing mushrooms with a spatula halfway through. Let cool in pan; mushrooms will continue to crisp as they cool. To finish, add some milk to the soup and use an immersion blender to puree it in the pot, or puree in a blender. (Cover lid with a clean kitchen towel.) Taste and season with more salt and pepper if needed. Divide soup among bowls and top with shiitake bacon. Garnish with thyme sprigs and a drizzle of chili oil. Serves 4-6. — “Mastering the Art of Plant-Based Cooking” by Joe Yonan PG tested Velvety cranberry beans simmered with tomato and the punch of red wine vinegar are a perfect match for a soft bed of cheesy polenta. This is a filling, stick-to-your-ribs dish perfect for fall. 1/4 cup olive oil 1 small onion, finely chopped 2 garlic cloves, minced 2 cups canned chopped tomatoes, juice reserved 1 tablespoon red wine vinegar 2 tablespoons tomato paste 1 cup chicken or vegetable broth 4 fresh sage leaves Salt and pepper 4 cups cooked Lamon or cranberry beans 2 cups uncooked polenta 6 ounces pancetta, diced Chopped fresh basil or parsley, for garnish Grated Parmesan cheese, for serving In large pan, heat olive oil over medium heat. Add onion and garlic and cook, stirring, until onion begins to soften, about 3 minutes. Stir in tomatoes and red wine vinegar. In a small bowl, dissolve tomato paste in the broth and add to pan. Stir in sage and season with salt and pepper. Simmer, stirring occasionally, until the sauce has thickened, 15-20 minutes. Add beans to tomato sauce. Cook, stirring frequently, until heated through, about 15 minutes. Meanwhile, prepare polenta according to package instructions. Place pancetta in a small saucepan over low heat. Cook, stirring frequently, until the pancetta is brown and crisp, about 15 minutes. Use a slotted spoon to transfer pancetta to a paper towel to drain. To serve, spoon polenta into serving dishes. Ladle the beans over the polenta and top with the pancetta. Garnish with fresh basil and serve with grated Parmesan. Serves 6. — “The Bean Book: 100 Recipes for Cooking with All Kinds of Beans” by Steve Sando PG tested Beans and seafood might seen like an unusual pairing, but in this recipe, mild white beans take on a lot of flavor from clams. Spanish chorizo adds a nice contrast. 4 cups cooked white beans, bean broth reserved 1/4 cup extra-virgin olive oil 1/2 white onion, chopped 2 garlic cloves, chopped 1 teaspoon salt, or to taste 1/2 cup finely chopped Spanish-style cured chorizo 2 plum tomatoes, chopped 1/2 cup dry white wine 2 pounds small clams, scrubbed well Chopped fresh parsley, for garnish Country-style bread and butter, for serving In large pot, heat beans in their broth over medium-low heat. In large lidded saucepan, warm olive oil over medium-low heat. Add onion, garlic and salt and cook until soft, about 5 minutes. Add chorizo and cook gently until some of the fat has rendered, about 5 minutes. Add tomatoes and wine and cook to allow the flavors to mingle, 5-6 minutes. Increase heat to medium and add clams. Cover and cook for about 5 minutes, shaking the pan occasionally. Uncover the pan and cook until all of the clams open, another few minutes. Remove pan from heat, then remove and discard any clams that failed to open. Add clam mixture to the bean pot and stir very gently until well mixed. Simmer for a few minutes to allow the flavors to mingle but not get mushy. Ladle into large, shallow bowls and sprinkle with parsley. Set out a large bowl for discarded shells and encourage guests to eat with their fingers. Pass plenty of good bread and creamy butter at the table Serves 4-6. — “The Bean Book: 100 Recipes for Cooking with All Kinds of Beans, from the Rancho Gordo Kitchen” by Steve Sando with Julia Newberry PG tested So easy to pull together for your next party! 1 1/2 cups cooked cannellini beans, drained and rinsed 2 tablespoons extra-virgin olive oil Juice and zest of 1 lemon 1 small garlic clove, minced Generous pinch of salt Freshly ground black pepper 2 or 3 tablespoons water, if needed 2 fresh basil leaves, chopped, optional 1 sprig fresh rosemary, leaves chopped, optional In a food processor, pulse cannellini beans, olive oil, lemon juice and zest, garlic, salt and several grinds of pepper until combined. If it’s too thick, slowly add the water with the food processor running until it is smooth and creamy. Blend in the basil and/or rosemary, if using Serve with veggies, pita or bruschetta. Makes 1 1/2 cups — Gretchen McKay, Post-Gazette ©2024 PG Publishing Co. Visit at post-gazette.com. Distributed by Tribune Content Agency, LLC.Ruud van Nistelrooy treated himself to a beer after enjoying a perfect start to his reign as Leicester manager. Van Nistelrooy’s first game in charge ended with a 3-1 win over West Ham, thanks to goals from Jamie Vardy, Bilal El Khannouss and Patson Daka. The Dutchman, who was out of work for just two weeks following his four-game spell as Manchester United interim boss, only started on Sunday so was happy to end a hectic three days in style. “It has been very busy getting to know everyone, start working together,” he said. “Everybody was involved with that and helping, it was busy, long days, but worth it. I was focused on the game and what the game needed, the subs, the half-time talk, so focused on the moment, so I am going to get myself a little beer and reflect on the last three days.” He endured a dream start as Vardy scored after just 98 seconds with El Khannouss and Daka adding second-half goals. It was by no means one-way traffic, though, as West Ham – who scored a consolation through Niclas Fullkrug at the death – had 30 shots on goal. But Van Nistelrooy saw enough to think he can deliver on his objective of keeping the Foxes in the Premier League. “I am very happy, if you look at the result – and it is about the result – it was a great night, three points, three good goals and also very effective. Ruud at the wheel 🛞 — Leicester City (@LCFC) “Overall the game of course we have seen and how dominant West Ham were at certain stages and what they created, that is a fact and something we have to look at. “Overall, what I expected of the players going forward was togetherness and hunger, energy and spirit in this team that is fighting for every inch. “Eleven players on the pitch who are fighting as a foundation to play the rest of the Premier League. I saw that completely with every single player that started and came on. “That’s the foundation we have to build on, without that it will be impossible to get where we want to go. I am very happy about that.” West Ham’s hierarchy will have seen what impact a managerial change can have as the jury remains out on Julen Lopetegui, with away fans making their feelings clear by chanting “You’re getting sacked in the morning”. Lopetegui expects to keep his job but forthcoming games against his former club Wolves, Bournemouth, Brighton and Southampton could determine the Spaniard’s future. “The only thing that I am worried about is to go to training session tomorrow and stand up the players and prepare the next challenge,” he said. “We have one month of December with a lot of matches and I am sure with this attitude we are going to achieve many more points. “I believe in the players. I am confident that tomorrow we are going to be ready to prepare the next match. “Understanding the question, but at the end of the season maybe we talk in another way. There are a lot of matches and points, a lot of things can happen. “I believe in these players and team, I am sure the position is going to be much better. They are only words but we have to work a lot to achieve this.”
Results Summary 1 SUNNYVALE, Calif. , Dec. 4, 2024 /PRNewswire/ -- Synopsys, Inc. (Nasdaq: SNPS ) today reported results for its fourth quarter and fiscal year 2024. Revenue for the fourth quarter of fiscal year 2024 was $1.636 billion , compared to $1.467 billion for the fourth quarter of fiscal year 2023. Revenue for fiscal year 2024 was $6.127 billion , an increase of approximately 15% from $5.318 billion in fiscal year 2023. "The fourth quarter was a strong finish to a transformational year for Synopsys. We achieved record financial results while doubling down on our strategy with the sale of our Software Integrity business and the pending acquisition of Ansys," said Sassine Ghazi , president and CEO of Synopsys. "Looking ahead, the AI-driven reinvention of compute is accelerating the pace, scale and complexity of technology R&D, which expands our opportunity to solve engineering challenges from silicon to systems." "Continued strong execution drove excellent Q4 results, which exceeded the midpoint of our guidance targets and capped a year of 15% revenue growth for the company," said Shelagh Glaser , CFO of Synopsys. "The combination of our execution focus, operating discipline, and the critical nature of our industry-leading technology positions us well for the future. In 2025, we expect to deliver double-digit revenue growth grounded in pragmatism given continued macro uncertainties and the impact of our fiscal year calendar change." Synopsys' previously announced acquisition of Ansys is expected to close in the first half of 2025, subject to the receipt of required regulatory approvals and other customary closing conditions. This week marked the expiration of the Hart-Scott-Rodino (HSR) Act waiting period, and Synopsys is working cooperatively with Federal Trade Commission (FTC) staff to conclude the investigation and the staff's review of Synopsys' proposed remedies. _______________________________________________ 1 On September 30, 2024, Synopsys completed the sale of its Software Integrity business. Synopsys' Software Integrity business has been presented as a discontinued operation in the consolidated financial statements for all periods presented herein and all financial results and targets are presented herein on a continuing operations basis unless otherwise noted. Continuing Operations On September 30, 2024 , Synopsys completed the sale of its Software Integrity business. Unless otherwise noted, Synopsys' Software Integrity business has been presented as a discontinued operation in the Synopsys' consolidated financial statements for all periods presented herein and all financial results and targets are presented herein on a continuing operations basis. GAAP Results On a U.S. generally accepted accounting principles (GAAP) basis, net income for the fourth quarter of fiscal year 2024 was $279.3 million , or $1.79 per diluted share, compared to $346.1 million , or $2.23 per diluted share, for the fourth quarter of fiscal year 2023. GAAP net income for fiscal year 2024 was $1.442 billion , or $9.25 per diluted share, compared to $1.227 billion , or $7.91 per diluted share, for fiscal year 2023. Non-GAAP Results On a non-GAAP basis, net income for the fourth quarter of fiscal year 2024 was $529.9 million , or $3.40 per diluted share, compared to non-GAAP net income of $464.1 million , or $3.00 per diluted share, for the fourth quarter of fiscal year 2023. Non-GAAP net income for fiscal year 2024 was $2.058 billion , or $13.20 per diluted share, compared to non-GAAP net income of $1.636 billion , or $10.54 per diluted share, for fiscal year 2023. For a reconciliation of net income, earnings per diluted share and other measures on a GAAP and non-GAAP basis, see "GAAP to Non-GAAP Reconciliation" in the accompanying tables below. Business Segments Synopsys reports revenue and operating income in two segments: (1) Design Automation, which includes our advanced silicon design, verification products and services, system integration products and services, digital, custom and field programmable gate array IC design software, verification software and hardware products, manufacturing software products and other and (2) Design IP, which includes our interface, foundation, security, and embedded processor IP, IP subsystems, and IP implementation services. Financial Targets Synopsys also provided its consolidated financial targets for the first quarter and full fiscal year 2025. These targets reflect a change in Synopsys' fiscal year from a 52/53-week period ending on the Saturday nearest to October 31 of each year to October 31 of each year. As a result of this change, there will be ten fewer days in the first half of fiscal year 2025 and two extra days in the second half of fiscal year 2025, which results in eight fewer days in the aggregate in Synopsys' fiscal year 2025 as compared to its fiscal year 2024. These targets also assume no further changes to export control restrictions or the current U.S. government "Entity List" restrictions. These targets constitute forward-looking statements and are based on current expectations. For a discussion of factors that could cause actual results to differ materially from these targets, see "Forward-Looking Statements" below. First Quarter and Full Fiscal Year 2025 Financial Targets (1) (in millions except per share amounts) Range for Three Months Ending Range for Fiscal Year Ending January 31, 2025 October 31, 2025 Low High Low High Revenue $ 1,435 $ 1,465 $ 6,745 $ 6,805 GAAP Expenses $ 1,142 $ 1,162 $ 4,926 $ 4,983 Non-GAAP Expenses $ 945 $ 955 $ 4,045 $ 4,085 Non-GAAP Interest and Other Income (Expense), net $ 20 $ 22 $ 94 $ 98 Non-GAAP Tax Rate 16 % 16 % 16 % 16 % Outstanding Shares (fully diluted) 156 158 157 159 GAAP EPS $ 1.81 $ 1.95 $ 10.42 $ 10.63 Non-GAAP EPS $ 2.77 $ 2.82 $ 14.88 $ 14.96 Operating Cash Flow ~ $1,800 Free Cash Flow (2) ~ $1,600 Capital Expenditures ~ $170 (1) Synopsys' first quarter of fiscal year 2025 will end on January 31, 2025 and its fiscal year 2025 will end on October 31, 2025. (2) Free cash flow is calculated as cash provided from operating activities less capital expenditures. For a reconciliation of Synopsys' first quarter and fiscal year 2025 targets, including expenses, earnings per diluted share and other measures on a GAAP and non-GAAP basis and a discussion of the financial targets that we are not able to reconcile without unreasonable efforts, see "GAAP to Non-GAAP Reconciliation" in the accompanying tables below. Earnings Call Open to Investors Synopsys will hold a conference call for financial analysts and investors today at 2:00 p.m. Pacific Time. A live webcast of the call will be available on Synopsys' corporate website at investor.synopsys.com . Synopsys uses its website as a tool to disclose important information about Synopsys and comply with its disclosure obligations under Regulation Fair Disclosure. A webcast replay will also be available on the corporate website from approximately 5:30 p.m. Pacific Time today through the time Synopsys announces its results for the first quarter of fiscal year 2025 in February 2025. Effectiveness of Information The targets included in this press release, the statements made during the earnings conference call, the information contained in the financial supplement and the corporate overview presentation, each of which are available on Synopsys' corporate website at www.synopsys.com (collectively, the " Earnings Materials "), represent Synopsys' expectations and beliefs as of December 4, 2024 . Although these Earnings Materials will remain available on Synopsys' website through the date of the earnings call for the first quarter of fiscal year 2025, their continued availability through such date does not mean that Synopsys is reaffirming or confirming their continued validity. Synopsys undertakes no duty and does not intend to update any forward-looking statement, whether as a result of new information or future events, or otherwise update, the targets given in this press release unless required by law. Availability of Final Financial Statements Synopsys will include final financial statements for the fiscal year 2024 in its annual report on Form 10-K to be filed on or before January 2, 2025 . About Synopsys Catalyzing the era of pervasive intelligence, Synopsys, Inc. (Nasdaq: SNPS) delivers trusted and comprehensive silicon to systems design solutions, from electronic design automation to silicon IP and system verification and validation. We partner closely with semiconductor and systems customers across a wide range of industries to maximize their R&D capability and productivity, powering innovation today that ignites the ingenuity of tomorrow. Learn more at www.synopsys.com . Reconciliation of Fourth Quarter and Fiscal Year 2024 Results The following tables reconcile the specific items excluded from GAAP in the calculation of non-GAAP net income, earnings per diluted share, and tax rate for the periods indicated below. GAAP to Non-GAAP Reconciliation of Fourth Quarter and Fiscal Year 2024 Results (1) (unaudited and in thousands, except per share amounts) Three Months Ended Twelve Months Ended October 31, October 31, 2024 2023 2024 2023 GAAP net income from continuing operations attributed to Synopsys $ 279,281 $ 346,051 $ 1,441,710 $ 1,227,045 Adjustments: Amortization of acquired intangible assets 54,258 14,886 104,220 50,477 Stock-based compensation 165,116 128,286 656,632 511,730 Acquisition/divestiture related items 62,428 4,016 172,638 13,831 Restructuring charges — (1,348) — 53,091 Gain on sale of strategic investments — — (55,077) — Tax settlement — — — (23,752) Tax adjustments (31,158) (27,753) (262,322) (196,471) Non-GAAP net income from continuing operations attributed to Synopsys $ 529,925 $ 464,138 $ 2,057,801 $ 1,635,951 Three Months Ended Twelve Months Ended October 31, October 31, 2024 2023 2024 2023 GAAP net income from continuing operations per diluted share attributed to Synopsys $ 1.79 $ 2.23 $ 9.25 $ 7.91 Adjustments: Amortization of acquired intangible assets 0.35 0.10 0.67 0.33 Stock-based compensation 1.06 0.83 4.21 3.30 Acquisition/divestiture related items 0.40 0.03 1.11 0.09 Restructuring charges — (0.01) — 0.34 Gain on sale of strategic investments — — (0.35) — Tax settlement — — — (0.15) Tax adjustments (0.20) (0.18) (1.69) (1.28) Non-GAAP net income from continuing operations per diluted share attributed to Synopsys $ 3.40 $ 3.00 $ 13.20 $ 10.54 Shares used in computing net income per diluted share amounts: 155,991 154,845 155,944 155,195 (1) Synopsys' fourth quarter of fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter. GAAP to Non-GAAP Tax Rate Reconciliation (1)(2) (unaudited) Twelve Months Ended October 31, 2024 GAAP effective tax rate 6.6 % Stock-based compensation 2.9 % Income tax adjustments (3) 5.5 % Non-GAAP effective tax rate 15.0 % (1) Synopsys' fiscal year 2024 ended on November 2, 2024. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter. (2) Presented on a continuing operations basis. (3) The adjustments are primarily related to the differences in the tax rate effect of certain deductions, such as the deduction for foreign-derived intangible income and credits. GAAP to Non-GAAP Reconciliation of 2025 Targets The following tables reconcile the specific items excluded from GAAP in the calculation of non-GAAP targets for the periods indicated below. GAAP to Non-GAAP Reconciliation of First Quarter Fiscal Year 2025 Targets (in thousands, except per share amounts) Range for Three Months Ending January 31, 2025 Low High Target GAAP expenses $ 1,142,000 $ 1,162,000 Adjustments: Amortization of acquired intangible assets (12,000) (15,000) Stock-based compensation (185,000) (192,000) Target non-GAAP expenses $ 945,000 $ 955,000 Range for Three Months Ending January 31, 2025 Low High Target GAAP earnings per diluted share attributed to Synopsys $ 1.81 $ 1.95 Adjustments: Amortization of acquired intangible assets 0.10 0.08 Stock-based compensation 1.22 1.18 Acquisition/divestiture related items (1) 0.08 0.06 Tax adjustments (0.44) (0.45) Target non-GAAP earnings per diluted share attributed to Synopsys $ 2.77 $ 2.82 Shares used in non-GAAP calculation (midpoint of target range) 157,000 157,000 GAAP to Non-GAAP Reconciliation of Full Fiscal Year 2025 Targets (in thousands, except per share amounts) Range for Fiscal Year Ending October 31, 2025 Low High Target GAAP expenses $ 4,926,000 $ 4,983,000 Adjustments: Amortization of acquired intangible assets (46,000) (51,000) Stock-based compensation (835,000) (847,000) Target non-GAAP expenses $ 4,045,000 $ 4,085,000 Range for Fiscal Year Ending October 31, 2025 Low High Target GAAP earnings per diluted share attributed to Synopsys $ 10.42 $ 10.63 Adjustments: Amortization of acquired intangible assets 0.32 0.29 Stock-based compensation 5.36 5.28 Acquisition/divestiture related items (1) 0.29 0.26 Tax adjustments (1.51) (1.50) Target non-GAAP earnings per diluted share attributed to Synopsys $ 14.88 $ 14.96 Shares used in non-GAAP calculation (midpoint of target range) 158,000 158,000 (1) Adjustments reflect certain contractually obligated financing fees and related amortization expenses, and do not fully reflect all potential adjustments for future periods for the reasons set forth in "GAAP to Non-GAAP Reconciliation" below. Forward-Looking Statements This press release and the investor conference call contain forward-looking statements, including, but not limited to, statements regarding short-term and long-term financial targets, expectations and objectives including, among others, our long-term financial objectives, which include the anticipated effects of our pending acquisition of ANSYS, Inc. (the Ansys Merger); business and market outlook, opportunities, strategies and technological trends, such as artificial intelligence; planned acquisitions and their expected impact, including the Ansys Merger; the potential impact of the uncertain macroeconomic and geopolitical environment on our financial results; the expected impact of U.S. and foreign government trade restrictions and regulatory changes, including export control restrictions and tariffs on our financial results; customer license renewals and the expected realization and timing of our contracted but unsatisfied or partially unsatisfied performance obligations (backlog); planned dispositions and their expected impact; customer demand and market expansion for our products and our customers' products; our ability to successfully compete in the markets we serve; our planned product releases and capabilities; industry growth rates; software trends; planned stock repurchases; our expected tax rate; and the impact and result of pending legal, regulatory, administrative and tax proceedings. These statements involve risks, uncertainties and other factors that could cause our actual results, time frames or achievements to differ materially from those expressed or implied in such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: macroeconomic conditions and geopolitical uncertainty in the global economy; uncertainty in the growth of the semiconductor and electronics industries; the highly competitive industry we operate in; actions by the U.S. or foreign governments, such as the imposition of additional export restrictions or tariffs; consolidation among our customers and our dependence on a relatively small number of large customers; risks and compliance obligations relating to the global nature of our operations; failure to complete the Ansys Merger on the terms described in our filings with the SEC, if at all; failure to obtain required governmental approvals related to the Ansys Merger or the imposition of conditions to such governmental approvals that may have an adverse effect on us; failure to realize the benefits expected from the Ansys Merger; and more. Additional information on potential risks, uncertainties and other factors that could affect Synopsys' results is included in filings we make with the SEC from time to time, including in the sections entitled "Risk Factors" in our latest Annual Report on Form 10-K and in our latest Quarterly Report on Form 10-Q. The financial information contained in this press release should be read in conjunction with the consolidated financial statements and notes thereto included in Synopsys' most recent reports on Forms 10-K and 10-Q, each as may be amended from time to time. Synopsys' financial results for its fourth quarter and fiscal year 2024 are not necessarily indicative of Synopsys' operating results for any future periods. The information provided herein is as of December 4, 2024 . Synopsys undertakes no duty to, and does not intend to, update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law. SYNOPSYS, INC. Unaudited Consolidated Statements of Income (1) (in thousands, except per share amounts) Three Months Ended Twelve Months Ended October 31, October 31, 2024 2023 2024 2023 Revenue: Time-based products $ 834,375 $ 780,725 $ 3,224,299 $ 3,016,256 Upfront products 520,939 441,494 1,802,222 1,400,125 Total products revenue 1,355,314 1,222,219 5,026,521 4,416,381 Maintenance and service 280,672 245,164 1,100,915 901,633 Total revenue 1,635,986 1,467,383 6,127,436 5,318,014 Cost of revenue: Products 216,485 197,540 770,238 697,686 Maintenance and service 91,707 76,043 367,055 287,876 Amortization of acquired intangible assets 66,831 12,598 107,996 45,281 Total cost of revenue 375,023 286,181 1,245,289 1,030,843 Gross margin 1,260,963 1,181,202 4,882,147 4,287,171 Operating expenses: Research and development 554,818 465,815 2,082,360 1,849,935 Sales and marketing 219,225 186,953 859,342 724,934 General and administrative 172,032 102,271 568,496 376,677 Amortization of acquired intangible assets 4,086 3,346 16,238 9,295 Restructuring charges — (1,348) — 53,091 Total operating expenses 950,161 757,037 3,526,436 3,013,932 Operating income 310,802 424,165 1,355,711 1,273,239 Interest and other income (expense), net 12,077 (20,400) 158,147 32,231 Income before income taxes 322,879 403,765 1,513,858 1,305,470 Provision (benefit) for income taxes 62,084 60,409 99,718 90,188 Net income from continuing operations 260,795 343,356 1,414,140 1,215,282 Income from discontinued operations, net of income taxes 834,825 3,139 821,670 2,843 Net income 1,095,620 346,495 2,235,810 1,218,125 Less: Net income (loss) attributed to non-controlling interest and redeemable non-controlling interest (18,486) (2,695) (27,570) (11,763) Net income attributed to Synopsys $ 1,114,106 $ 349,190 $ 2,263,380 $ 1,229,888 Net income attributed to Synopsys Continuing operations $ 279,281 $ 346,051 $ 1,441,710 $ 1,227,045 Discontinued operations 834,825 3,139 821,670 2,843 Net income $ 1,114,106 $ 349,190 $ 2,263,380 $ 1,229,888 Net income per share attributed to Synopsys - basic: Continuing operations $ 1.81 $ 2.28 $ 9.41 $ 8.06 Discontinued operations 5.43 0.02 5.37 0.02 Basic net income per share $ 7.24 $ 2.30 $ 14.78 $ 8.08 Net income per share attributed to Synopsys - diluted: Continuing operations $ 1.79 $ 2.23 $ 9.25 $ 7.91 Discontinued operations 5.35 0.03 5.26 0.01 Diluted net income per share $ 7.14 $ 2.26 $ 14.51 $ 7.92 Shares used in computing per share amounts: Basic 153,916 151,972 153,138 152,146 Diluted 155,991 154,845 155,944 155,195 (1) Synopsys' fourth quarter of fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter. SYNOPSYS, INC. Unaudited Consolidated Balance Sheets (1) (in thousands, except par value amounts) October 31, 2024 October 31, 2023 ASSETS: Current assets: Cash and cash equivalents $ 3,896,532 $ 1,433,966 Short-term investments 153,869 151,639 Total cash, cash equivalents and short-term investments 4,050,401 1,585,605 Accounts receivable, net 934,470 856,660 Inventories 361,849 325,590 Prepaid and other current assets 1,122,946 548,115 Current assets of discontinued operations — 114,654 Total current assets 6,469,666 3,430,624 Property and equipment, net 563,006 549,837 Operating lease right-of-use assets, net 565,917 559,923 Goodwill 3,448,850 3,346,065 Intangible assets, net 195,164 239,577 Deferred income taxes 1,247,258 853,526 Other long-term assets 583,700 444,820 Long-term assets of discontinued operations — 908,759 Total assets $ 13,073,561 $ 10,333,131 LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND STOCKHOLDERS' EQUITY: Current liabilities: Accounts payable and accrued liabilities $ 1,163,592 $ 1,059,914 Operating lease liabilities 94,791 79,832 Deferred revenue 1,391,737 1,559,461 Current liabilities of discontinued operations — 286,244 Total current liabilities 2,650,120 2,985,451 Long-term operating lease liabilities 574,065 579,686 Long-term deferred revenue 340,831 150,827 Long-term debt 15,601 18,078 Other long-term liabilities 469,738 381,531 Long-term liabilities of discontinued operations — 33,257 Total liabilities 4,050,355 4,148,830 Redeemable non-controlling interest 30,000 31,043 Stockholders' equity: Preferred stock, $0.01 par value: 2,000 shares authorized; none outstanding — — Common stock, $0.01 par value: 400,000 shares authorized; 154,112 and 152,053 shares outstanding, respectively 1,541 1,521 Capital in excess of par value 1,211,206 1,276,152 Retained earnings 8,984,105 6,741,699 Treasury stock, at cost: 3,148 and 5,207 shares, respectively (1,025,770) (1,675,650) Accumulated other comprehensive income (loss) (180,380) (196,414) Total Synopsys stockholders' equity 8,990,702 6,147,308 Non-controlling interest 2,504 5,950 Total stockholders' equity 8,993,206 6,153,258 Total liabilities, redeemable non-controlling interest and stockholders' equity $ 13,073,561 $ 10,333,131 (1) Synopsys' fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter. SYNOPSYS, INC. Unaudited Consolidated Statements of Cash Flows (1) (in thousands) Twelve Months Ended 2024 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 2,235,810 $ 1,218,125 Adjustments to reconcile net income to net cash provided by operating activities: Amortization and depreciation 295,065 247,120 Reduction of operating lease right-of-use assets 97,273 97,705 Amortization of capitalized costs to obtain revenue contracts 73,587 82,190 Stock-based compensation 692,316 563,292 Allowance for credit losses 19,724 19,932 Gain on sale of strategic investments (55,077) — Gain on divestitures, net of transaction costs (868,830) — Amortization of bridge financing costs 33,677 — Deferred income taxes (407,649) (211,045) Other (1,295) 13,295 Net changes in operating assets and liabilities, net of effects from acquisitions and dispositions: Accounts receivable (103,460) (178,432) Inventories (51,449) (123,752) Prepaid and other current assets (410,432) (106,396) Other long-term assets (168,255) (100,618) Accounts payable and accrued liabilities 187,564 170,496 Operating lease liabilities (96,966) (73,281) Income taxes (73,215) 198,078 Deferred revenue 8,641 (113,435) Net cash provided by operating activities 1,407,029 1,703,274 CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from maturities and sales of short-term investments 138,961 130,435 Purchases of short-term investments (136,821) (131,079) Proceeds from sales of strategic investments 55,696 8,492 Purchases of strategic investments (1,293) (435) Purchases of property and equipment, net (123,161) (189,618) Acquisitions, net of cash acquired (156,947) (297,692) Proceeds from business divestiture, net of cash divested 1,446,578 — Capitalization of software development costs — (2,204) Net cash provided by (used in) investing activities 1,223,013 (482,101) CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of debt (2,607) (2,603) Payment of bridge financing and term loan costs (72,265) — Issuances of common stock 232,212 252,986 Payments for taxes related to net share settlement of equity awards (337,541) (241,408) Purchase of equity forward contract — (45,000) Purchases of treasury stock — (1,160,724) Other (1,096) (122) Net cash used in financing activities (181,297) (1,196,871) Effect of exchange rate changes on cash, cash equivalents and restricted cash 8,797 (2,979) Net change in cash, cash equivalents and restricted cash 2,457,542 21,323 Cash, cash equivalents and restricted cash, beginning of year, including cash from discontinued operations 1,441,187 1,419,864 Cash, cash equivalents and restricted cash, end of period, including cash from discontinued operations 3,898,729 1,441,187 Less: Cash, cash equivalents and restricted cash from discontinued operations — 4,947 Cash, cash equivalents and restricted cash from continuing operations $ 3,898,729 $ 1,436,240 (1) Synopsys' fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter. Synopsys provides segment information, namely revenue, adjusted segment operating income and adjusted segment operating margin, in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 280, Segment Reporting. Synopsys' chief operating decision maker (" CODM ") is our Chief Executive Officer. In evaluating our business segments, the CODM considers the income and expenses that the CODM believes are directly related to those segments. The CODM does not allocate certain operating expenses managed at a consolidated level to our business segments and, as a result, the reported operating income and operating margin do not include these unallocated expenses as shown in the table below. These unallocated expenses are presented in the table below to provide a reconciliation of the total adjusted operating income from segments to our consolidated operating income from continuing operations: SYNOPSYS, INC. Business Segment Reporting (1)(2)(5) (in millions) Three Months Ended October 31, 2024 Three Months Ended October 31, 2023 Twelve Months Ended October 31, 2024 Twelve Months Ended October 31, 2023 Revenue by segment - Design Automation $ 1,118.2 $ 953.7 $ 4,221.1 $ 3,775.3 % of Total 68.3 % 65.0 % 68.9 % 71.0 % - Design IP $ 517.8 $ 513.7 $ 1,906.3 $ 1,542.7 % of Total 31.7 % 35.0 % 31.1 % 29.0 % Adjusted operating income by segment - Design Automation $ 413.3 $ 311.1 $ 1,631.9 $ 1,413.9 - Design IP $ 189.9 $ 236.4 $ 730.2 $ 514.1 Adjusted operating margin by segment - Design Automation 37.0 % 32.6 % 38.7 % 37.5 % - Design IP 36.7 % 46.0 % 38.3 % 33.3 % Total Adjusted Segment Operating Income Reconciliation (1)(2)(5) (in millions) Three Months Ended October 31, 2024 Three Months Ended October 31, 2023 Twelve Months Ended October 31, 2024 Twelve Months Ended October 31, 2023 GAAP total operating income – as reported $ 310.8 $ 424.2 $ 1,355.7 $ 1,273.2 Other expenses managed at consolidated level -Amortization of acquired intangible assets (3) 70.9 15.9 124.2 54.6 -Stock-based compensation (3) 165.4 128.6 657.9 513.1 -Non-qualified deferred compensation plan 9.2 (23.9) 85.4 20.2 -Acquisition/divestiture related items (4) 47.0 4.0 138.7 13.8 -Restructuring charges — (1.3) — 53.1 Total adjusted segment operating income $ 603.2 $ 547.5 $ 2,362.1 $ 1,928.0 (1) Synopsys manages the business on a long-term, annual basis, and considers quarterly fluctuations of revenue and profitability as normal elements of our business. Amounts may not foot due to rounding. (2) Synopsys' fourth quarter of fiscal year 2024 and 2023 ended on November 2, 2024 and October 28, 2023, respectively. For presentation purposes, we refer to the closest calendar month end. Fiscal year 2024 was a 53-week year, which included an extra week in the first quarter. (3) The adjustment includes non-GAAP expenses attributable to non-controlling interest and redeemable non-controlling interest. (4) The adjustment excludes the amortization of bridge financing costs entered into in connection with the pending acquisition of Ansys, that was recorded in interest and other income (expense), net, in our unaudited condensed consolidated statements of income. (5) Presented on a continuing operations basis. GAAP to Non-GAAP Reconciliation Synopsys continues to provide all information required in accordance with GAAP but acknowledges evaluating its ongoing operating results may not be as useful if an investor is limited to reviewing only GAAP financial measures. Accordingly, Synopsys presents non-GAAP financial measures in reporting its financial results to provide investors with an additional tool to evaluate Synopsys' operating results in a manner that focuses on what Synopsys believes to be its core business operations and what Synopsys uses to evaluate its business operations and for internal budgeting and resource allocation purposes. This press release includes non-GAAP earnings per diluted share, non-GAAP net income and non-GAAP tax rate for the periods presented. It also includes future estimates for non-GAAP expenses, non-GAAP interest and other income (expense), non-GAAP tax rate, non-GAAP earnings per diluted share and free cash flow. These non-GAAP financial measures may be different from non-GAAP financial measures used by other companies. When possible, Synopsys provides a reconciliation of non-GAAP financial measures to their most closely applicable GAAP financial measures. Synopsys is unable to provide a full reconciliation of certain first quarter and full fiscal year 2025 non-GAAP financial targets to the corresponding GAAP financial measures on a forward-looking basis because Synopsys believes that it would not be possible for it to have the required information necessary to quantitatively reconcile such measures with sufficient precision without unreasonable efforts due to, among other things, the potential variability and limited predictability of the excluded adjustment items necessary for a full reconciliation such as certain acquisition/divestiture related items, restructuring charges, tax deduction variability, changes in the fair value of non-qualified deferred compensation plan, and gains (losses) on the sale of strategic investments. For the same reasons, Synopsys is unable to address the probable significance of the unavailable information. Synopsys' management does not itself, nor does it suggest that investors should, consider such non-GAAP financial measures in isolation from, as superior to, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are meant to supplement, and be viewed in conjunction with, the corresponding GAAP financial measures. Synopsys' management believes presentation of non-GAAP financial measures, when shown in conjunction with the corresponding GAAP financial measures, provides useful information to investors allowing them to view financial and business trends relating to our financial condition and results of operations through the eyes of management. Synopsys' management evaluates and makes decisions about our business operations using both GAAP financial measures and non-GAAP financial measures to help facilitate internal comparisons to Synopsys' historical operating results and forecasted targets, planning and forecasting in subsequent periods and comparisons to competitors' operating results. The following are descriptions of the adjustments made to reconcile non-GAAP financial measures (other than free cash flow, which is defined in the footnote to the Financial Targets table above) to the most directly comparable GAAP financial measures: (i) Amortization of acquired intangible assets. We incur expenses from amortization of acquired intangible assets, which may include impairment charges from write-downs of acquired intangible assets. Acquired intangible assets include, among other things, core/developed technology, customer relationships, contract rights, trademarks and trade names, and other intangibles related to acquisitions. We amortize the intangible assets over their estimated useful lives. We do not enter into acquisitions on a predictable cycle. The amount of an acquisition's purchase price allocated to intangible assets and their estimated useful lives can vary significantly and are unique to each acquisition. From time to time, we incur impairment charges due to write-downs of acquired intangible assets. We believe that the presentation of non-GAAP financial measures that adjust for the amortization of intangible assets, including impairment charges, provides investors and others with a consistent basis for comparison across accounting periods. We also exclude this item because such expenses are non-cash in nature and we believe the non-GAAP financial measures excluding this item provide meaningful supplemental information regarding our core operational performance and liquidity, and ability to invest in research and development and fund future acquisitions and capital expenditures. (ii) Stock-based compensation . Stock-based compensation expenses consist primarily of expenses related to restricted stock units, stock options, employee stock purchase rights and other stock awards, including such expenses associated with acquisitions. We exclude stock-based compensation expense from our non-GAAP financial measures primarily because it is not an expense that typically requires or will require cash settlement by us. Further, the expense for the fair value of the stock-based instruments we utilize may bear little resemblance to the actual value realized upon the vesting or future exercise of the related stock-based awards and, therefore, is not used by management to assess the core profitability of our business operations. (iii) Acquisition/divestiture related items. In connection with certain of our business combinations and/or divestitures, we incur significant expenses that we would not have otherwise incurred as part of our business operations. These expenses include, among other things, compensation expenses, professional fees and other direct expenses, concurrent restructuring activities and divestiture activities, including employee severance and other exit costs, bridge financing costs, costs related to integration activities, changes to the fair value of contingent consideration related to the acquired company, and amortization of the fair value difference of below-market value assets arising from arrangements entered into or acquired in conjunction with an acquisition. We also recognize the gains and losses from the mark-up of equity or cost method investments to fair value upon obtaining control through acquisition. We exclude these items because they are related to acquisitions and have no direct correlation to the core operation of our business. Further, because we do not acquire businesses on a predictable cycle and the terms of each transaction can vary significantly and are unique to each transaction, we believe it is useful to exclude such expenses when looking for a consistent basis for comparison across accounting periods. (iv) Restructuring charges. We initiate restructuring activities to align our costs to our operating plans and business strategies based on then-current economic conditions, and such activities have a specific and defined term. Restructuring costs generally include severance and other termination benefits related to voluntary retirement programs, involuntary headcount reductions and facilities closures. Such restructuring costs include elimination of operational redundancy, permanent reductions in workforce and facilities closures and, therefore, are not considered by us to be a part of the core operation of our business and are not used by management when assessing the core profitability and performance of our business operations. (v) Gains (losses) on the sale of strategic investments. We exclude gains and losses on the sale of equity investments in privately held companies because we do not believe they are reflective of our core business and operating results. (vi) Deferred compensation . We exclude changes in the fair value of our non-qualified deferred compensation plan because we do not use these to assess the core profitability of our business operations. (vii) Income tax effect of non-GAAP pre-tax adjustments . Excluding the income tax effect of non-GAAP pre-tax adjustments from the provision for income taxes assists investors in understanding the tax provision associated with those adjustments and the effect on net income. We utilize an annual non-GAAP tax rate in calculating non-GAAP financial measures to provide better consistency across interim reporting periods by eliminating the effects of certain non-recurring and other period-specific items, which can vary in size and frequency and do not necessarily reflect our normal operations, and to more closely align our tax rate with our expected geographic earnings mix. This annual non-GAAP tax rate is based on an evaluation of our historical and projected mix of U.S. and international profit before tax, taking into account the impact of non-GAAP adjustments, U.S. tax law changes, as well as other factors such as our current tax structure, existing tax positions and expected recurring tax incentives. Based on these considerations, we have elected to adopt a non-GAAP tax rate of 16% for fiscal year 2025. INVESTOR CONTACT : Trey Campbell Synopsys, Inc. 650-584-4289 Synopsys-ir@synopsys.com EDITORIAL CONTACT : Cara Walker Synopsys, Inc. 650-584-5000 corp-pr@synopsys.com View original content to download multimedia: https://www.prnewswire.com/news-releases/synopsys-posts-financial-results-for-fourth-quarter-and-fiscal-year-2024-302322901.html SOURCE Synopsys, Inc.Lawyers, loyalists and Wall Street executives: a look at who's on Trump's tariff team
5A All-Idaho girls soccer team: The state’s best players from every corner of Idaho
Telerehabilitation Systems Market to Expand by USD 532.9 Million (2024-2028), Rising Chronic Disease Cases Driving Revenue, AI Impacting Market Trends - Technavio
- Previous: slot ace
- Next: slot jackpot monitoring system
